Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

162.13
-0.5700-0.35%
Post-market: 164.542.41+1.48%17:28 EDT
Volume:3.07M
Turnover:498.45M
Market Cap:251.46B
PE:24.27
High:163.75
Open:162.70
Low:161.95
Close:162.70
52wk High:212.71
52wk Low:145.79
Shares:1.55B
Float Shares:1.50B
Volume Ratio:1.07
T/O Rate:0.20%
Dividend:3.23
Dividend Rate:1.99%
EPS(TTM):6.68
EPS(LYR):6.54
ROE:21.96%
ROA:8.02%
PB:5.00
PE(LYR):24.79

Loading ...

AstraZeneca announces Etcamah with CDK4/6 inhibitor approved in EU

TIPRANKS
·
Jul 23

Astrazeneca's Etcamah combination for ESR1-mutated advanced breast cancer

MT Newswires Live
·
Jul 23

European Union Grants Approval to AstraZeneca's New Breast Cancer Medication

Stock News
·
Jul 23

Astrazeneca PLC Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 23

What Bundibugyo Ebola Vaccines and Treatments are Under Development

Reuters
·
Jul 22

Royalty Pharma Acquires Royalty Interest in AstraZeneca's Cliramitug

MT Newswires Live
·
Jul 22

Jefferies Sticks to Its Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Jul 22

AstraZeneca Halts Russian NMOSD Study: What It Means for AZN Investors

TIPRANKS
·
Jul 22

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Jul 21

Astrazeneca PLC Stock Falls Monday, Underperforms Market

Dow Jones
·
Jul 21

Market Chatter: AstraZeneca Unit Highlights Opportunities in Rare Diseases

MT Newswires Live
·
Jul 20

Earning Preview: AstraZeneca PLC this quarter’s revenue is expected to increase by 10.06%, and institutional views are bullish

Earnings Agent
·
Jul 20

AstraZeneca’s New Saruparib Trial Targets Next Wave of Prostate Cancer Growth

TIPRANKS
·
Jul 18

AstraZeneca’s ALICIA Real‑World CLL Study Wraps Up, Setting Up Fresh Data for AZN Investors

TIPRANKS
·
Jul 18

European Pharma Stocks' Underperformance Shouldn't Last

Dow Jones
·
Jul 17

Morgan Stanley Remains a Buy on AstraZeneca (AZN)

TIPRANKS
·
Jul 17

AstraZeneca price target lowered to 15,300 GBp at Morgan Stanley

TIPRANKS
·
Jul 17

Astrazeneca PLC Stock Rises Thursday, Outperforms Market

Dow Jones
·
Jul 17

AstraZeneca’s Eluminate-4 Trial Targets High-Risk Diabetes Patients, Raising Long-Term Upside for AZN

TIPRANKS
·
Jul 16

Movement Alert|AstraZeneca Rises 3.07% in Regular Trading, $1.5 Billion Lung Cancer Drug Licensing Deal Boosts Sentiment

Market Focus
·
Jul 15